Chad Ritch, MD, discusses differences between PSMA-PET imaging agents and the need for further evidence to guide clinical decision-making.
|Videos|March 17, 2020
PCa focal therapy: Who are the best candidates?
In this video, Scott Eggener, MD, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.
Advertisement
In this video, Scott Eggener, MD, of the University of Chicago, outlines which patients are the best candidates for focal therapy for prostate cancer, and discusses the differences in follow-up for patients treated with focal therapy compared with those undergoing active surveillance.
Advertisement
Related to this article
Chad Ritch, MD, discusses how PSMA-PET informs patient management across different stages of the prostate cancer journey.
Alicia K. Morgans, MD, MPH, reviews promising prostate cancer findings from ESMO 2026,
Alberto Briganti, MD, PhD, discusses results from the PROTEUS substudy, evaluating perioperative apalutamide plus ADT vs surgery alone in high-risk localized or locally advanced prostate cancer.
Carlos A. Vargas, MD, discusses updated survival outcomes, safety, and the mechanism of SYNC-T SV-102, an investigational in situ immunotherapy for metastatic prostate cancer.
Kim Chi, MD, FRCPC, discusses the rationale and design of the phase 3 KLK2-comPAS trial evaluating pasritamig alone and in combination with JNJ-9401 in patients with mCRPC.
Jeffrey M. Spier, MD, reviews evidence on ARPI dose reduction in prostate cancer and discusses monitoring treatment response, tolerability, and dose reescalation.
Jeffrey M. Spier, MD, discusses managing ARPI-related fatigue through dose adjustments, patient monitoring, and strategies to maintain treatment adherence.
Advertisement
Advertisement
Trending on Urology Times
1
Factors shaping PSMA-PET agent selection in prostate cancer
2
Nogapendekin alfa inbakicept plus BCG advances to final analysis in BCG-naïve NMIBC
3
Chad Ritch, MD, on using PSMA-PET to guide treatment decisions
4
Alicia Morgans, MD, MPH, highlights key prostate cancer data from ESMO 2026
5